Korea Investment CORP raised its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 40.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,729 shares of the medical equipment provider’s stock after purchasing an additional 7,990 shares during the quarter. Korea Investment CORP owned 0.06% of ABIOMED worth $12,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Janney Montgomery Scott LLC boosted its stake in ABIOMED by 16.3% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,039 shares of the medical equipment provider’s stock worth $834,000 after purchasing an additional 286 shares during the period. Cullen Frost Bankers Inc. bought a new position in ABIOMED in the 2nd quarter worth about $425,000. Piedmont Investment Advisors LLC bought a new position in ABIOMED in the 2nd quarter worth about $196,000. Massachusetts Financial Services Co. MA boosted its stake in ABIOMED by 231.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 142,969 shares of the medical equipment provider’s stock worth $58,482,000 after purchasing an additional 99,780 shares during the period. Finally, Dupont Capital Management Corp boosted its stake in ABIOMED by 698.4% in the 2nd quarter. Dupont Capital Management Corp now owns 4,415 shares of the medical equipment provider’s stock worth $1,806,000 after purchasing an additional 3,862 shares during the period. Hedge funds and other institutional investors own 84.88% of the company’s stock.
ABMD has been the topic of several recent analyst reports. Morgan Stanley raised ABIOMED from an “equal” rating to a “weight” rating and raised their price target for the company from $396.00 to $496.00 in a report on Wednesday, November 7th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. ValuEngine raised ABIOMED from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective on the stock in a report on Friday, November 2nd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $402.78.
Shares of ABIOMED stock opened at $332.68 on Friday. The company has a market capitalization of $14.95 billion, a price-to-earnings ratio of 135.79, a P/E/G ratio of 2.71 and a beta of 0.35. ABIOMED, Inc. has a one year low of $186.72 and a one year high of $459.75.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.36. The business had revenue of $181.78 million for the quarter, compared to analysts’ expectations of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business’s quarterly revenue was up 36.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.54 EPS. As a group, equities analysts predict that ABIOMED, Inc. will post 3.57 earnings per share for the current fiscal year.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Story: Asset Allocation and Your Retirement
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.